Molecular Formula: C₁₀H₁₅N₃O₅
Molar mass: 257.2432 g/mol
Density: 1.541 g/cm₃
Flash Point: 301 °C
Index of Refraction: 1.678
Boiling Point: 574.2 °C at 760 mmHg
Vapour Pressure: 5.06E-14 mmHg at 25°C
Structure of Benserazide (CAS NO.322-35-0):

XLogP3-AA: -1.3
H-Bond Donor: 7
H-Bond Acceptor: 7
IUPAC Name: 2-Amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
Canonical SMILES: C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O
InChI: InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-
2,6,12,14-17H,3-4,11H2,(H,13,18) 
InChIKey: BNQDCRGUHNALGH-UHFFFAOYSA-N

 Benserazide (CAS NO.322-35-0) is not approved for use in the US; carbidopa is used instead for the same purpose. These combinations are also used for the treatment of restless legs syndrome.It is used in the management of Parkinson's disease in combination with L-DOPA (levodopa) as co-beneldopa (BAN), under the brand names Prolopa in Canada and Madopar in the UK, both made by Roche.

 Benserazide ,its cas register number is 322-35-0. Benserazide (CAS NO.322-35-0) is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor, which is unable to cross the blood-brain barrier, and also can be called N-(DL-Seryl)-N'-(2,3,4-trihydroxybenzyl) Hydrazine ; 2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanohydrazide ; DL-Serine 2-[(2,3,4-Trihydroxyphenyl)methyl] Hydrazide ; Benserazidum and Serazide .
 Benserazide (CAS NO.322-35-0) has little therapeutic effect on its own, and is only administered in combination with levodopa.Most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood-brain barrier, this translates to little therapeutic gain with strong peripheral side effects. Benserazide inhibits this decarboxylation.Adverse effects caused by peripheral dopamine. However, benserazide cannot reduce the centrally-mediated side effects of levodopa, particularly dyskinesia.